Eurand

Eurand, which is based in Amsterdam, markets Zenpep in the United States.

Eurand, Nycomed reach marketing deal for Zenpep - Yahoo! Finance 2011

We currently have a Neutral recommendation on Eurand, which is supported by a Zacks #3 Rank

Axcan to Acquire Eurand - Yahoo! Finance 2010

Eurand agreed to be acquired by Axcan Holdings for $583 million, after an " extended auction process " for the Netherlands specialty pharmaceutical company.

Business Watch 2010

Also Wednesday, specialty pharmaceutical company Eurand said it has agreed to be acquired by Axcan Holdings for $12 per share in cash, for a total value of about $583 million.

Stocks Cap Week With Elway Like Comeback MarketNewsVideo.com 2010

Specialty drug maker Eurand added 1.01, or 7.5%, to 14.46, after the Food and Drug Administration approved its pancreatic enzyme drug Zenpep.

Small-Cap Stocks Post Second Losing Week in Seven 2009

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies.

unknown title 2011

Investors and Eurand shareholders are strongly advised to carefully read the tender offer statement including the offer to purchase, letter of transmittal and other offer documents and the related solicitation/recommendation statement before any decision is made with respect to the Tender Offer because they will contain important information.

unknown title 2011

Eurand is a global company with facilities in the U.S. and Europe.

unknown title 2011

The offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, are available to all shareholders of Eurand at no expense to them from the information agent, Okapi Partners LLC, by directing a request to sgannon@axcan.com or (450) 467-2600 ext. 2442 or from Eurand by directing a request to Eurand at bill.newbould@eurand.com or (267) 759-9335.

unknown title 2011

On December 21, 2010, Axcan Pharma Holding B.V., a wholly owned subsidiary of Axcan Holdings, Inc., commenced its Tender Offer to acquire all of the outstanding ordinary shares of Eurand, N.V. at a purchase price of $12.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes.

unknown title 2011